AgelessRx, a telehealth longevity platform, has been selected as one of ten finalists in the $101 million XPRIZE Healthspan competition and awarded $1 million to advance its clinical trial. The company's approach layers established gerotherapeutics—including low-dose naltrexone, metformin, rapamycin, and NAD+—with structured exercise and meditation, tested on a direct-to-consumer model rather than within traditional academic walls.
Key Points
- Multi-agent intervention targeting muscle, cognition, immune function in adults 50-90
- Pilot data from 26 participants showed feasibility of combined pharmacological and lifestyle approac
- Direct-to-consumer telehealth model democratizes access to age-reversal research protocols
Longevity Analysis
The distinction here is architectural rather than chemical. Recognizing that aging operates through multiple independent pathways—not a single biological bottleneck—requires interventions that address regeneration, energy production, hormonal signaling, and structural resilience simultaneously. AgelessRx's framework removes barriers to access by delivering these layered protocols through telehealth infrastructure rather than confining rigorous research to academic medical centers. The planned phase-three trial (186 participants, one year, fully powered) will clarify whether this multi-system, multi-mechanism approach produces measurable functional restoration in the 50-to-90 age band. The underlying logic is sound: no single agent reverses aging comprehensively, and coordinated intervention across distinct physiological systems may succeed where single-target approaches plateau.
Original published by Longevity.Technology, by Kyle Umipig.